MLH1 and neoplasm: Finally, we did not find MLH1 promoter methylation more frequently in either recurrent neoplasms or in primary neoplasms exposed to neoadjuvant chemotherapy, nor was MLH1 methylation identified in the neoplastic pair with reduced MLH1 expression in the recurrence.